Low
₹5,635.00
High
₹5,727.50
| Previous Close | ₹5,669.50 |
|---|---|
| Day's Range | ₹5,635.00 - ₹5,727.50 |
| Open | ₹5,699.00 |
| 52 Week Range | ₹4,731.60 - ₹5,933.50 |
| Volume | 1,04,124 |
| Market Cap | ₹0.07 |
| Trade Value ( ₹ in Lacs) | 5,901.41 |
|---|---|
| Market Cap (₹ in Mn) | 0.07 |
| Dividend Yield(%) | 0.93 |
| Price/Earning (TTM) | 29.45 |
| TTM EPS (₹) | 192.51 |
| P/E Ratio | 26.94 |
| Book Value(₹) | 4.91 |
| PAT Margin (%) | 11.48 |
| Face Value (₹) | 2.00 |
| ROCE(%) | 21.56 |
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 88134.4 | 31437.5 |
| Expenses | N/A | N/A |
| PBT | 23035.4 | 3957.2 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 22808.9 | 3223.9 |
| Founded | 1973 |
|---|---|
| Managing Director | Sandeep Singh |
| NSE Symbol | ALKEM |
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,64,331.30 | 1,935.25 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,81,466.36 | 6,832.30 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,65,951.64 | 4,895.20 | 3,309.40 - 3,309.40 |
| Apollo Hospitals Enterprise Ltd. | 1,27,127.92 | 8,843.70 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,16,228.74 | 1,438.75 | 1,165.70 - 1,165.70 |
| Zydus Lifesciences Ltd. | 1,14,762.82 | 1,150.50 | 835.50 - 835.50 |
| Lupin Ltd. | 1,14,128.12 | 2,496.90 | 1,836.80 - 1,836.80 |
| Max Healthcare Institute Ltd. | 1,07,853.30 | 1,108.15 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 1,04,275.29 | 2,526.55 | 1,909.70 - 1,909.70 |
| Dr. Reddy's Laboratories Ltd. | 1,03,958.87 | 1,245.50 | 1,148.40 - 1,148.40 |
No Records Found
Pursuant to Regulation 30 and 47 read alongwith Schedule III of the SEBI LODR Regulations, Alkem Laboratories has informed that it enclosed a copy of advertisement published in today's newspapers, Business Standard (English) and Mumbai Lakshadeep (Marathi) for information regarding 52nd Annual General Meeting of the Company to be held through video conferencing (VC)/ other audio visual means (OAVM). The same is also available on the website of the Company at www.alkemlabs.com.
The above information is a part of company’s filings submitted to BSE.
In continuation of its earlier intimations dated 13th February, 2026 and 06th March, 2026, wherein the Stock Exchanges were informed that Alkem Medtech, a wholly owned subsidiary of the Company in India (‘Alkem Medtech’), intends to acquire at least 51% and up to 55% of the total issued equity share capital of Occlutech Holding AG(‘Occlutech’), a company incorporated in Switzerland and had executed Share Purchase Agreement with the selling shareholders of Occlutech respectively. In this regard, Alkem Laboratories has informed that on 26th June, 2026, Alkem Medtech has executed First Supplementary Agreement to Share Purchase Agreement dated 6th March, 2026 with the selling shareholders of Occlutech. A copy of this disclosure will be made available on the Company’s website in accordance with Regulation 30(8) of the SEBI LODR Regulations.
The above information is a part of company’s filings submitted to BSE.
No Records Found
The current share price of Alkem Laboratories Ltd. is ₹5,669.50 as of 2026-07-10.
The market capitalisation of Alkem Laboratories Ltd. is ₹67,789.77 as of 2026-07-10.
The 1-year return of Alkem Laboratories Ltd. is 862.80% as of 2026-07-10.
The P/E ratio of Alkem Laboratories Ltd. is 26.94 as of 2026-07-12.
The 52-week high and low of Alkem Laboratories Ltd. are ₹5,933.50 and ₹4,731.60, respectively, as of 2026-07-10.
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.